Victory Capital Management
SMMT icon

Victory Capital Management’s Summit Therapeutics SMMT Stock Holding History

Victory Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,267
Closed -$22.9K – 2634
2023
Q3 		$22.9K Buy
12,267
+364
+3% +$694 ﹤0.01% 2440
2023
Q2 		$29.9K Sell
11,903
-277
-2% -$506 ﹤0.01% 2427
2023
Q1 		$21.3K Buy
+12,180
New +$33.2K ﹤0.01% 2503

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

Victory Capital Management's SMMT Position: Q4 2023 in Review

Victory Capital Management sold out of Summit Therapeutics (SMMT) in Q4 2023, closing a stake of 12,267 shares — an estimated $22.9K sold.

Victory Capital Management first reported a position in SMMT in Q1 2023 and held it in 3 quarters. The position peaked at $29.9K in Q2 2023. 97 funds tracked by Wall St. Rank hold SMMT as of Q4 2023.

  • Victory Capital Management reported no remaining Summit Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Victory Capital Management sold 12,267 Summit Therapeutics shares in Q4 2023, an estimated $22.9K.
  • Victory Capital Management first reported a position in Summit Therapeutics in Q1 2023 and held it in 3 quarters.
  • Victory Capital Management's Summit Therapeutics position peaked at $29.9K in Q2 2023.
  • 97 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2023.

Based on Victory Capital Management's 13F filing for Q4 2023, filed 5 Feb 2024.